- Home
- LRMR vs PVLA Comparison
LRMR vs PVLA Comparison
Compare LRMR & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- PVLA
- Stock Information
- Founded
- LRMR N/A
- PVLA 2015
- Country
- LRMR United States
- PVLA United States
- Employees
- LRMR N/A
- PVLA N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- LRMR Health Care
- PVLA Health Care
- Exchange
- LRMR Nasdaq
- PVLA Nasdaq
- Market Cap
- LRMR 309.8M
- PVLA 285.2M
- IPO Year
- LRMR N/A
- PVLA N/A
- Fundamental
- Price
- LRMR $3.96
- PVLA $54.63
- Analyst Decision
- LRMR Strong Buy
- PVLA Strong Buy
- Analyst Count
- LRMR 8
- PVLA 12
- Target Price
- LRMR $17.88
- PVLA $59.00
- AVG Volume (30 Days)
- LRMR 1.3M
- PVLA 126.1K
- Earning Date
- LRMR 10-29-2025
- PVLA 11-15-2025
- Dividend Yield
- LRMR N/A
- PVLA N/A
- EPS Growth
- LRMR N/A
- PVLA N/A
- EPS
- LRMR N/A
- PVLA N/A
- Revenue
- LRMR N/A
- PVLA N/A
- Revenue This Year
- LRMR N/A
- PVLA N/A
- Revenue Next Year
- LRMR N/A
- PVLA N/A
- P/E Ratio
- LRMR N/A
- PVLA N/A
- Revenue Growth
- LRMR N/A
- PVLA N/A
- 52 Week Low
- LRMR $1.61
- PVLA $11.17
- 52 Week High
- LRMR $9.50
- PVLA $61.48
- Technical
- Relative Strength Index (RSI)
- LRMR 54.10
- PVLA 58.33
- Support Level
- LRMR $3.78
- PVLA $49.81
- Resistance Level
- LRMR $4.26
- PVLA $61.48
- Average True Range (ATR)
- LRMR 0.27
- PVLA 4.41
- MACD
- LRMR -0.00
- PVLA -0.46
- Stochastic Oscillator
- LRMR 55.14
- PVLA 41.31
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.